Literature DB >> 10825585

The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses.

R E Brouwer1, M van der Hoorn, H C Kluin-Nelemans, S van Zelderen-Bhola, R Willemze, J H Falkenburg.   

Abstract

To increase the immunogenicity of leukemic cells, attempts were made to generate dendritic-like antigen presenting cells (DC) from AML blasts from 14 patients with AML FAB classifications M0-M5. Leukemic cells were cultured in the presence or absence of various cytokines including GM-CSF, SCF, TNF-alpha, IL-4, and gamma-interferon. After various intervals recovery of viable cells was measured and expression of CD80, CD86, CD40, CD54, CD58, and CD11a was analyzed by flow cytometry. Functionally, DC derived from six AML samples were tested in a mixed lymphocyte response (MLR) using HLA-DR mismatched donor T cells as responder cells. Proliferation (5/14) or increased survival (7/14) of AML cells was observed in the presence of GM-CSF, SCF, and TNF-alpha. Only in the AML M2, M3, and M4 FAB subtypes proliferation was found. GM-CSF, SCF, and TNF-alpha induced morphologic changes typical for DC and increased the expression of costimulatory and adhesion molecules. No significant effect of IL-4 or gamma-interferon was observed. The day of maximal expression of these molecules varied. In cases with minor upregulation of CD80 or CD86, no further stimulation using CD40-L activation was observed. In the three cases tested, the DC-like cells retained the chromosomal abnormalities present in the original AML cells. In five out of six cases tested an increase in allostimulatory capacity was found at the day of maximal expression of costimulatory and adhesion molecules. In two patients a decrease in stimulatory capacity was found at day 7 compared with day 2 correlating with a decreased expression of these molecules. In conclusion, AML cells can be induced to increase their stimulatory capacity by upregulating costimulatory and adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825585     DOI: 10.1016/s0198-8859(00)00111-7

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.

Authors:  Kambiz Bagheri; Kamran Alimoghadam; Ali Akbar Pourfathollah; Zuhair Muhammad Hassan; Jamshid Hajati; Seyyed Mohammad Moazzeni
Journal:  Pathol Oncol Res       Date:  2008-09-20       Impact factor: 3.201

2.  The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.

Authors:  Takahide Tsuchiya; Masao Hagihara; Yasuhito Shimakura; Yoko Ueda; Balgansuren Gansuvd; Batmunkh Munkhbat; Hiroyasu Inoue; Kei Tazume; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 3.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

Review 4.  Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

Authors:  Liam J O'Brien; Camille Guillerey; Kristen J Radford
Journal:  Cancers (Basel)       Date:  2019-06-22       Impact factor: 6.575

5.  PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.

Authors:  Daniel Christoph Amberger; Fatemeh Doraneh-Gard; Carina Gunsilius; Melanie Weinmann; Sabine Möbius; Christoph Kugler; Nicole Rogers; Corinna Böck; Uwe Ködel; Jan-Ole Werner; Doris Krämer; Britta Eiz-Vesper; Andreas Rank; Christoph Schmid; Helga Maria Schmetzer
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 6.  Dendritic cell-based immunotherapy for myeloid leukemias.

Authors:  Christian M Schürch; Carsten Riether; Adrian F Ochsenbein
Journal:  Front Immunol       Date:  2013-12-31       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.